Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 11/20 | 0.52 |
| ▸ | CFD | P00746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21713030 | 0.86 | KLKB1 (0.65) | KLKB1CFD | |
| SCHEMBL31033223 | 0.86 | KLKB1 (0.65) | KLKB1CFD | |
| SCHEMBL21736634 | 0.81 | KLKB1 (0.65) | KLKB1CFDKDM4E | |
| SCHEMBL21736858 | 0.79 | KLKB1 (0.64) | KLKB1 | |
| SCHEMBL31741485 | 0.79 | KLKB1 (0.64) | KLKB1 | |
| SCHEMBL31741497 | 0.76 | KLKB1 (0.66) | KLKB1CFD | |
| SCHEMBL21736623 | 0.76 | KLKB1 (0.66) | KLKB1CFD | |
| SCHEMBL23769365 | 0.76 | KLKB1 (0.51) | KLKB1CFDKDM4E | |
| SCHEMBL23769343 | 0.76 | KLKB1 (0.49) | KLKB1CFDKDM4ENTRK1 | |
| SCHEMBL21713084 | 0.74 | KLKB1 (0.43) | KLKB1CFDKDM4ENTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885CFD 703/4885KDM4E 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.